President and CEO of Tracon Pharmaceuticals Inc (30-Year Financial, Insider Trades) Charles Theuer (insider trades) bought 44,843 shares of TCON on 08/18/2020 at an average price of $1.63 a share. The total cost of this purchase was $73,094.
TRACON Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The company is engaged in the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration and fibrotic diseases. TRACON Pharmaceuticals Inc has a market cap of $13.690 million; its shares were traded at around $1.61 . TRACON Pharmaceuticals Inc had annual average EBITDA growth of 0.90% over the past five years. GuruFocus has detected 2 severe warning signs with TRACON Pharmaceuticals Inc. .
CEO Recent Trades:
-
President and CEO Charles Theuer bought 44,843 shares of TCON stock on 08/18/2020 at the average price of $1.63. The price of the stock has decreased by 1.23% since.
-
President and CEO Charles Theuer bought 20,000 shares of TCON stock on 08/13/2020 at the average price of $1.73. The price of the stock has decreased by 6.94% since.
For the complete insider trading history of TCON, click here
.This article first appeared on GuruFocus.